This was determined by assessing the percentage area positive for pan-cytokeratin (CK), a pan-breast cancer cell marker, α-SMA; a myofibroblast marker, and CD68 as a pan-macrophage marker. This evidence concerns the gene CD68 and breast carcinoma.